ProCE Banner Activity

Ibrutinib and the Management of Patients With del(17p) CLL

Clinical Thought
How ibrutinib earned its place among first-line treatment options for patients with CLL and del(17p)

Released: March 23, 2015

Expiration: March 21, 2016

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from Boehringer Ingelheim.